Stockscreener 앱 받기
0.1638
1.80%
-0.003
시간 외 거래:
.17
0.0062
+3.79%
전일 마감가:
$0.1668
열려 있는:
$0.17
하루 거래량:
1.22M
Relative Volume:
0.25
시가총액:
$13.98M
수익:
-
순이익/손실:
$-31.88M
주가수익비율:
-0.2184
EPS:
-0.75
순현금흐름:
$-25.20M
1주 성능:
-4.77%
1개월 성능:
+8.41%
6개월 성능:
-50.91%
1년 성능:
-83.59%
1일 변동 폭
$0.1581
$0.17
1주일 범위
$0.1581
$0.176
52주 변동 폭
$0.133
$1.74
인에잇바이오 Stock (INAB) Company Profile
명칭
In 8 Bio Inc
전화
(646) 600-6438
주소
EMPIRE STATE BUILDING, NEW YORK
INAB을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
INAB
In 8 Bio Inc
|
0.1638 | 13.98M | 0 | -31.88M | -25.20M | -0.75 |
|
VRTX
Vertex Pharmaceuticals Inc
|
450.03 | 129.44B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
558.52 | 61.42B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
615.11 | 38.44B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
269.81 | 33.29B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
241.75 | 26.95B | 3.81B | -644.79M | -669.77M | -6.24 |
인에잇바이오 Stock (INAB) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-03-18 | 개시 | Laidlaw | Buy |
| 2022-08-30 | 개시 | H.C. Wainwright | Buy |
인에잇바이오 주식(INAB)의 최신 뉴스
INmune Bio Inc. to Report First Quarter 2025 Financial Results and Provide Corporate Update on Thursday, May 8th - TradingView
Press Release Distribution & PR Platform - ACCESS Newswire
Nuvation Bio CFO to Share Latest Oncology Strategy at Exclusive Citizens Conference Next Week - Stock Titan
Palisade Bio’s AI-Driven Approach to IBD Heterogeneity and - GlobeNewswire
Annovis Bio Appoints Hui Liu as Director of Biostatistics - GlobeNewswire
Belite Bio Announces Poster Presentations at the Association for Research in Vision and Ophthalmology 2025 Annual Meeting - Yahoo Finance
Cerity Partners LLC Makes New Investment in Nuvation Bio Inc. (NYSE:NUVB) - Defense World
TELA Bio to Announce Q1 2025 Earnings on May 8 - MSN
TELA Bio to Announce First Quarter 2025 Financial Results - The Manila Times
Tevogen Bio Signs Agreement with CD 8 Technology - TipRanks
Is Gossamer Bio Inc. (NASDAQ:GOSS) the Best Penny Stock to Invest in Under $1? - Insider Monkey
GRI Bio Announces Abstract Selected for Poster Discussion Session at the 2025 American Thoracic Society (ATS) International Conference - Yahoo Finance
Layoff Tracker: Mural Oncology Cuts 90% of Staff, Explores Strategic Alternatives - BioSpace
Vyant Bio (OTCMKTS:VYNT) Trading 7.8% Higher – Time to Buy? - Defense World
Palisade Bio Completes Dosing in Phase 1a Portion of Ongoing Phase 1a/b Study of PALI-2108 - GlobeNewswire
Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)April 8, 2025 - BioSpace
South Korean firms ABL Bio, Yuhan advance bispecific antibodies in cancer treatmentCHOSUNBIZ - Chosunbiz
High Growth Tech Stocks Including ABL Bio To Watch - Yahoo
ABL Bio lands $2.8 billion license-out deal with GSK - KED Global
GRI Bio Reports Encouraging Interim 2-Week Safety Results - GlobeNewswire
GRI Bio Reports Encouraging Interim 2-Week Safety Results from Ongoing Phase 2a Study of GRI-0621 in Idiopathic Pulmonary Fibrosis (“IPF”) - Yahoo Finance
KALA BIO Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update - TradingView
GRI Bio Bolsters Intellectual Property Portfolio with Granting of Two Global Patents for Europe and Japan - GlobeNewswire
SEC Form 424B5 filed by Instil Bio Inc. - Quantisnow
bluebird bio Confirms Receipt of an Unsolicited Non-Binding Proposal from Ayrmid - Yahoo Finance
Climb Bio to Present at the 24th Annual Needham Virtual Healthcare Conference - The Globe and Mail
Healthcare Spotlight: Climb Bio Takes Center Stage at Major Needham Conference - Stock Titan
Annovis to Attend AD/PD™ 2025 with Extensive Scientific Program - Quantisnow
Annovis Provides Corporate Updates and Reports Fourth Quarter and Fiscal Year 2024 Financial Results - Quantisnow
Entera Bio Ltd expected to post a loss of 8 cents a shareEarnings Preview - TradingView
Kronos Bio Inc (KRON) Q4 2024 Earnings: EPS Misses at -$0.43, Re - GuruFocus.com
GRI Bio Reports Full Year 2024 Financial Results and - GlobeNewswire
Short Interest in bluebird bio, Inc. (NASDAQ:BLUE) Drops By 26.8% - Defense World
10 Most Oversold Penny Stocks to Buy According to Analysts - Insider Monkey
Analysts Set Nuvation Bio Inc. (NYSE:NUVB) Target Price at $8.33 - Defense World
Gossamer Bio Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Palisade Bio Commences Dosing in First Ulcerative Colitis Patient Cohort in Ongoing Phase 1a/b Study of PALI-2108 - GlobeNewswire
Palisade Bio Announces Two Abstracts Selected to be - GlobeNewswire
Shareholder Alert: The Ademi Firm investigates whether 2seventy bio, Inc. is obtaining a Fair Price for its Public Shareholders - Joplin Globe
GRI Bio Regains Compliance with Nasdaq’s Minimum Bid Price Rule - GlobeNewswire
Why Paymentus Holdings Shares Are Trading Higher By Over 8%; Here Are 20 Stocks Moving Premarket - Benzinga
2seventy bio Enters into Definitive Agreement to be Acquired by Bristol Myers Squibb - Business Wire
Nuvation Bio Inc. (NUVB): Among the Best NYSE Penny Stocks to Buy According to Analysts - Yahoo Finance
Q32 Bio Inc expected to post a loss of $1.51 a shareEarnings Preview - TradingView
Nuvation Bio Inc reports results for the quarter ended December 31Earnings Summary - TradingView
One-step Cre-loxP organism creation by TAx9Communications Biology - Nature
Passage Bio Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Palisade Bio Participates in Virtual Investor “What This Means” Segment - GlobeNewswire
Tevogen Bio to Receive $8 Million of Non-Dilutive Grant Funding, Reiterates Efficient Operations - Yahoo Finance
Canadian North Resources Inc. Expands Metallurgical Programs Applying Low-carbon Footprint Bioleaching Technology on Ferguson Lake Ni-Cu-Co PGE project - Yahoo Canada Finance
인에잇바이오 (INAB) 재무 분석
매출
순이익
현금흐름
주당 순 이익
5.24%
자본화:
|
볼륨(24시간):